Study of GS-1423 in Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
For Phase 1a Part A, the primary objectives are to assess safety and tolerability and to
define the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) or recommended Phase
2 dose (RP2D) of GS-1423 monotherapy in participants with advanced solid tumors.
For Phase 1a Part B, the primary objective is to assess safety and tolerability of GS-1423
monotherapy in participants with advanced solid tumors.
For Phase 1b Cohort 1 safety run-in, the primary objective is to assess safety and
tolerability and to define the DLT and MTD or RP2D of GS-1423 in combination with a
chemotherapy regimen in participants with advanced gastric or gastroesophageal junction
adenocarcinoma.
For Phase 1b Cohort 1 post safety run-in, the primary objective is to assess the preliminary
efficacy of GS-1423 in combination with a chemotherapy regimen in participants with advanced
gastric or gastroesophageal junction adenocarcinoma, as assessed by the confirmed objective
response rate (ORR).
For Phase 1b Cohort 2, the primary objective is to assess safety and tolerability of GS-1423
monotherapy in participants with advanced solid tumors.